Genmab A/S ADR (GMAB) Social Stream
GENMAB A (GMAB) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering GENMAB A.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-11 | 6 | $50 | $37 | $44.8 | $37.36 | 19.91% |
| 2021-11-15 | 7 | $50 | $37 | $44.7 | $37.36 | 19.65% |
| 2022-01-18 | 8 | $50 | $37 | $44.7 | $37.36 | 19.65% |
| 2022-01-31 | 8 | $50 | $37 | $44.7 | $37.36 | 19.65% |
| 2022-02-28 | 8 | $50 | $37 | $42.2 | $37.36 | 12.96% |
| 2022-04-07 | 8 | $50 | $33 | $41.4 | $37.36 | 10.81% |
| 2022-04-11 | 9 | $50 | $33 | $41.416 | $37.36 | 10.86% |
| 2022-04-21 | 9 | $50 | $30 | $40.916 | $37.36 | 9.52% |
| 2022-05-02 | 10 | $50 | $30 | $40.5 | $37.36 | 8.4% |
| 2022-05-12 | 10 | $50 | $30 | $38.571 | $37.36 | 3.24% |
| 2022-05-13 | 10 | $50 | $30 | $37.9 | $37.36 | 1.45% |
| 2022-06-05 | 10 | $50 | $29 | $37.757 | $37.36 | 1.06% |
| 2022-07-20 | 11 | $53 | $29 | $38.003 | $37.36 | 1.72% |
| 2022-08-13 | 11 | $53 | $29 | $38.441 | $37.36 | 2.89% |
| 2022-08-15 | 11 | $53 | $31 | $38.691 | $37.36 | 3.56% |
| 2022-08-25 | 11 | $53 | $31 | $38.941 | $37.36 | 4.23% |
| 2022-10-19 | 11 | $53 | $31 | $39.316 | $37.36 | 5.24% |
| 2022-11-10 | 12 | $53 | $31 | $39.753 | $37.36 | 6.41% |
| 2022-11-14 | 12 | $53 | $33 | $40.128 | $37.36 | 7.41% |
| 2022-12-03 | 13 | $53 | $33 | $40.753 | $37.36 | 9.08% |
| 2023-01-03 | 13 | $53 | $33 | $42.091 | $37.36 | 12.66% |
| 2023-01-26 | 13 | $53 | $33 | $42.653 | $37.36 | 14.17% |
| 2023-02-22 | 13 | $53 | $34.73 | $43.028 | $37.36 | 15.17% |
| 2023-02-23 | 13 | $53 | $34.73 | $42.653 | $37.36 | 14.17% |
| 2023-02-26 | 13 | $54 | $34 | $42.653 | $37.36 | 14.17% |
| 2023-03-27 | 13 | $54 | $33 | $41.841 | $37.36 | 11.99% |
| 2023-04-20 | 13 | $54 | $33 | $41.341 | $37.36 | 10.66% |
| 2023-05-11 | 12 | $54 | $34.73 | $42.604 | $37.36 | 14.04% |
| 2023-05-16 | 11 | $54 | $33.001 | $41.716 | $37.36 | 11.66% |
| 2023-05-22 | 11 | $54 | $33.001 | $42.216 | $37.36 | 13% |
| 2023-05-25 | 12 | $54 | $33.001 | $43.216 | $37.36 | 15.67% |
| 2023-06-26 | 11 | $54 | $33.001 | $44.428 | $37.36 | 18.92% |
| 2023-08-03 | 12 | $54 | $33.001 | $44.428 | $37.36 | 18.92% |
| 2023-08-15 | 12 | $54 | $33 | $44.142 | $37.36 | 18.15% |
| 2023-08-24 | 13 | $54 | $33 | $44.125 | $37.36 | 18.11% |
| 2023-09-12 | 14 | $54 | $33 | $44.125 | $37.36 | 18.11% |
The Trend in the Analyst Price Target
Over the past 13 months, GMAB's average price target has gone up $5.18.
Over the past 49 weeks, GMAB's average upside potential has been 6.38%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-05 | 13 | 53 | 34.730 | 43.028 | 38.26 | 12.46% |
| 2023-04-20 | 13 | 54 | 33.000 | 41.341 | 40.69 | 1.6% |
| 2023-05-11 | 11 | 54 | 33.001 | 41.591 | 41.96 | -0.88% |
| 2023-05-22 | 11 | 54 | 33.001 | 42.216 | 42.37 | -0.36% |
| 2023-05-25 | 12 | 54 | 33.001 | 43.216 | 40.53 | 6.63% |
GMAB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.48 | 5 | 0 | 7 | 1 | 1 | 14 |
The Trend in the Broker Recommendations
Over the past 18 months, GMAB's average broker recommendation rating improved by 0.25.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, GENMAB A's upside potential (average analyst target price relative to current price) is higher than 638.78% of them.
- GMAB has a greater average analyst price target than 1063.22% of stocks in the large market cap category.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, GENMAB A's number of analysts covering the stock is higher than 3271.28% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, GENMAB A's variance in analysts' estimates is lower than -1299.08% of them.
In the Pharmaceutical Products industry, ELAN, APLS, and ZLAB are the three stocks most similar to GENMAB A regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding GMAB using the data that counts. Try POWR Ratings for free.